Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancerEdward M. Kennedy(Oncor (United States)), Lorena Lerner(Oncor (United States))Nature CommunicationsOctober 7, 202210.1038/s41467-022-33599-wCited by 40SaveCiteExport RISWatch citationsRelated PapersSTAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the α2-macroglobulin gene|Genes & Development|2003|117Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer|Research Square|2021|4